H2AX and cancer: The significant association was also found between the H2AFX rs7759 polymorphism and cancer risk under the heterozygous co-dominant model (AA versus AG): OR = 1.73, 95% CI 1.28 to 2.33; P = 0.024, after Benjamini-Hochberg correction and under the dominant genetic model (AA versus AG + GG): OR = 1.76, 95% CI 1.32 to 2.34; P = 0.0016, after Benjamini-Hochberg correction.